Professional Recommendations and Provider Behavior

• In Event: How Practice Environments Shape Physician Behavior and Workforce Decisions

Abstract

Provider responses to updated clinical guidelines play a central role in shaping health outcomes, yet the translation of high-quality trial evidence into real-world clinical practice remains poorly understood. In this study, we examine how physicians respond to new randomized controlled trial (RCT) evidence and whether that response generates the health improvements the evidence promises. We analyze physician behavioral changes following the publication of the ARRIVE trial in obstetrics, a landmark RCT which found that elective induction at 39 weeks can reduce cesarean delivery rates in low-risk, first-time pregnancies, a finding that generated significant attention across the obstetric community and rapidly influenced clinical practice guidelines.

Using nationally representative U.S. birth certificate data from 2016 to 2021, we document a rapid and sustained increase in 39-week inductions for low-risk first births of approximately 9% following the trial's release. Importantly, inductions increase not only among first births, the population studied in the ARRIVE trial, but also among subsequent births, suggesting meaningful "off-label" application of trial findings to patient populations outside the original study design. This pattern raises important questions about the boundaries of evidence-based medicine and the mechanisms through which clinicians generalize from trial populations to broader practice.

Despite this significant and measurable shift in clinical behavior, we find no corresponding decline in cesarean section rates for first births, the primary outcome the ARRIVE trial was designed to improve. This disconnect between provider response and anticipated downstream health benefits represents a substantively important finding. It suggests that the real-world context of clinical practice, including patient heterogeneity, provider discretion, institutional incentives, and selection into induction, may attenuate or eliminate benefits that were cleanly identified under trial conditions.

These findings carry direct implications for evidence-based policymaking in healthcare. When clinical guidelines change, policymakers often assume that provider uptake will translate into commensurate improvements in patient outcomes. Our results challenge that assumption and underscore the importance of pairing guideline dissemination with rigorous real-world evaluation, particularly in high-stakes obstetric settings where policy decisions directly affect maternal and infant health.

Author

• Raka Datta, Georgia State University
  Presenting Author